# Recursion Pharmaceuticals Secures $200 Million Offering and $10 Million Sanofi Milestone

- URL: https://stocks.freetheai.org/news/recursion-pharmaceuticals-secures-200-million-offering-and-10-million-sanofi-3628be
- Published: 2026-10-16T05:19:47Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:RXRX](https://stocks.freetheai.org/symbols/NASDAQ-RXRX), [NASDAQ:SNY](https://stocks.freetheai.org/symbols/NASDAQ-SNY)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) announced two major financial and strategic developments. The clinical-stage biotechnology company priced an underwritten public offering of 61.54 million Class A shares at $3.25 per share, expecting gross proceeds of approximately $200 million before fees. Institutional backers participating in the deal include Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management.

Separately, pharmaceutical partner Sanofi SA (NASDAQ:SNY) selected the first drug candidate from the companies' multi-program research partnership. Sanofi opted into an oral small molecule candidate aimed at treating inflammatory conditions, triggering a $10 million milestone payment to Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). This brings total upfront and milestone receipts from Sanofi SA (NASDAQ:SNY) to $144 million, with eligibility for over $300 million in potential future milestones alongside double-digit product royalties.

The additional capital strengthens the balance sheet of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) while validating its artificial-intelligence-driven drug discovery pipeline through partner adoption. Investors will monitor the expected closing of the stock offering, as well as progress toward Phase 1 clinical testing for the inflammatory disease candidate, which Sanofi SA (NASDAQ:SNY) plans to fund and advance in 2027.

## Key points

- Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) priced an offering of 61.54 million Class A shares at $3.25 each to raise roughly $200 million.
- Sanofi SA (NASDAQ:SNY) exercised its option on an oral small molecule drug candidate for inflammatory diseases developed with Recursion.
- The decision by Sanofi SA (NASDAQ:SNY) triggered a $10 million milestone payment, pushing cumulative payments to Recursion to $144 million.
- Sanofi SA (NASDAQ:SNY) will fund and lead further development of the candidate, targeting Phase 1 clinical trials in 2027.
- Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares rose 11.23% during regular trading to $4.16.

## Questions and answers

### Why is Recursion Pharmaceuticals stock trending?

Recursion Pharmaceuticals stock is trending after pricing a $200 million public offering of Class A shares and receiving a $10 million milestone payment from Sanofi, which selected its first drug candidate from their research collaboration.

### How much did Sanofi pay Recursion Pharmaceuticals?

Sanofi paid Recursion a $10 million milestone payment after selecting an oral small molecule candidate for inflammatory diseases. Total upfront and milestone payments from Sanofi to Recursion now stand at $144 million, with over $300 million in potential future milestones.

### When will the new Sanofi-Recursion drug enter clinical trials?

The oral small molecule candidate for inflammatory diseases is expected to enter Phase 1 clinical trials in 2027, with Sanofi funding and managing its continued development.